XiuGui Chen
Chief Tech/Sci/R&D Officer at TYK Medicines, Inc.
Profile
XiuGui Chen is currently the Senior VP-Clinical & Registration Department at TYK Medicines, Inc. Previously, he worked as a Medical Director at Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
He earned a doctorate degree from Shanghai University.
XiuGui Chen active positions
| Companies | Position | Start |
|---|---|---|
TYK Medicines, Inc.
 TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Chief Tech/Sci/R&D Officer | 31/07/2018 |
Former positions of XiuGui Chen
| Companies | Position | End |
|---|---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
 Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Chief Tech/Sci/R&D Officer | - |
Training of XiuGui Chen
| Shanghai University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd.
Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. Medical SpecialtiesHealth Technology Ascletis Biopharmaceutical (Hangzhou) Co. Ltd. engages in discovering and developing new treatments for cancer and infectious diseases. The firm is currently developing ALN-VSP, a systemically delivered RNAi therapeutic comprising of two siRNAs designed to target two genes critical for the growth and development of cancer cells. It provides services to the Chinese pharmaceutical markets. The company was founded by Jinxing Qi and Jinzi J. Wu in 2011 and is headquartered in Hangzhou, China. | Health Technology |
TYK Medicines, Inc.
TYK Medicines, Inc. Pharmaceuticals: MajorHealth Technology TYK Medicines, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the business of research, development and commercialization of pharmaceutical products and differentiated targeted therapies to address unmet medical needs in cancer treatment. The company was founded by Wu Yusheng on November 2, 2017 and is headquartered in Huzhou, China. | Health Technology |
- Stock Market
- Insiders
- XiuGui Chen
